- Home
- OPP vs URGN Comparison
OPP vs URGN Comparison
Compare OPP & URGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OPP
- URGN
- Stock Information
- Founded
- OPP 2010
- URGN 2004
- Country
- OPP United States
- URGN United States
- Employees
- OPP N/A
- URGN N/A
- Industry
- OPP Finance/Investors Services
- URGN Biotechnology: Pharmaceutical Preparations
- Sector
- OPP Finance
- URGN Health Care
- Exchange
- OPP Nasdaq
- URGN Nasdaq
- Market Cap
- OPP 199.8M
- URGN 181.2M
- IPO Year
- OPP N/A
- URGN 2017
- Fundamental
- Price
- OPP $8.53
- URGN $14.24
- Analyst Decision
- OPP
- URGN Strong Buy
- Analyst Count
- OPP 0
- URGN 8
- Target Price
- OPP N/A
- URGN $29.00
- AVG Volume (30 Days)
- OPP 108.0K
- URGN 4.1M
- Earning Date
- OPP 01-01-0001
- URGN 08-12-2025
- Dividend Yield
- OPP 14.41%
- URGN N/A
- EPS Growth
- OPP N/A
- URGN N/A
- EPS
- OPP N/A
- URGN N/A
- Revenue
- OPP N/A
- URGN $91,871,000.00
- Revenue This Year
- OPP N/A
- URGN $36.65
- Revenue Next Year
- OPP N/A
- URGN $88.35
- P/E Ratio
- OPP N/A
- URGN N/A
- Revenue Growth
- OPP N/A
- URGN 8.98
- 52 Week Low
- OPP $7.26
- URGN $3.42
- 52 Week High
- OPP $8.83
- URGN $18.15
- Technical
- Relative Strength Index (RSI)
- OPP 58.64
- URGN 64.26
- Support Level
- OPP $8.44
- URGN $13.55
- Resistance Level
- OPP $8.56
- URGN $14.66
- Average True Range (ATR)
- OPP 0.07
- URGN 0.83
- MACD
- OPP 0.00
- URGN -0.08
- Stochastic Oscillator
- OPP 77.78
- URGN 73.66
About OPP RiverNorth/DoubleLine Strategic Opportunity Fund Inc.
RiverNorth/DoubleLine Strategic Opportunity Fund Inc is a closed-end management investment company. The company's investment objective is to seek current income and overall total return.
About URGN UroGen Pharma Ltd.
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. Their flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with investigational candidate UGN-102 (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. Additionally, their immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, intended for both monotherapy and combination therapy. Revenue is generated from product sales.